痴呆症和轻度认知障碍在墨西哥人口中的流行:来自Mex-Cog的证据,这是一个协调认知评估协议研究
Silvia Mejia-Arango1, Miguel Arce Rentería2, Joseph L Saenz3
1Institute of Neuroscience, School of Medicine, University of Texas Rio Grande Valley, Harlingen, Texas, United States.
概括
痴呆症影响6.7%,轻度认知障碍 (MCI) 影响10%的老年墨西哥人. 预测因素包括年龄,教育,农村生活和心血管问题,突显了疾病负担的不平等.
科学领域:
- 神经学 神经学
- 流行病学 流行病学
- 老年学是指老年学的学科.
背景情况:
- 认知障碍,包括痴呆症和轻度认知障碍 (MCI),在全球范围内构成了重大公共卫生挑战.
- 估计不同人群中认知能力下降的患病率和确定认知能力下降的预测因素对于有针对性的干预措施至关重要.
研究的目的:
- 用墨西哥认知衰老辅助研究 (Mex-Cog) 来估计墨西哥痴呆症和MCI的患病率.
- 在墨西哥人口中确定与痴呆症和MCI相关的社会人口统计学,上下文和健康相关的预测因素.
主要方法:
- 利用了2016年墨西哥Cog研究浪潮的数据,这是墨西哥健康和衰老研究 (MHAS) 的子样本.
- 包括1629名60岁以上的参与者,他们接受了认知电池和告密者采访.
- 采用了强大的规范方法和MCI/痴呆症的算法分类,使用全国代表的抽样权重来估计患病率.
主要成果:
- 估计痴呆症的流行率为6.7% (95% CI:5.4,8.0) 和MCI的流行率为10% (95% CI:8.7,11.7).
- 痴呆症预测因素包括年龄较大,教育程度较低,农村居住,中风和心脏病发作史.
- MCI预测因素包括年龄较大,女性性别,低学历,农村居住和缺乏医疗保险.
结论:
- 墨西哥-Cog研究提供了可靠的痴呆和MCI在墨西哥的流行率估计.
- 研究结果表明,脑血管和心血管疾病,以及教育,农村和保险状况等社会经济因素,导致认知障碍的负担不平等.
- 这些结果强调了需要制定公共卫生战略,解决社会决定因素,以减轻墨西哥老龄化人口中MCI和痴呆症差异的需要.
相关概念视频
01:30Dementia
486
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
486
01:26Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
512
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
512
01:08Prevalence and Incidence
1.5K
In statistical epidemiology and health sciences, two essential metrics—prevalence and incidence—are fundamental for understanding disease dynamics within a population. These measures enable public health officials, epidemiologists, and researchers to assess the burden of diseases, allocate resources effectively, and design impactful public health policies and interventions.
Prevalence indicates the proportion of individuals in a population who have a specific disease or health...
Prevalence indicates the proportion of individuals in a population who have a specific disease or health...
1.5K